Evolus, Inc. (EOLS)

Market Cap	312.43M
Revenue (ttm)	285.82M +15.1%
Net Income (ttm)	-58.56M
EPS (ttm)	-0.91
Shares Out	64.82M
PE Ratio	n/a
Forward PE	339.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,433,975
Open	4.900
Previous Close	4.920
Day's Range	4.680 - 4.910
52-Week Range	4.680 - 17.120
Beta	0.92
Analysts	Strong Buy
Price Target	18.80 (+290.04%)
Earnings Date	Mar 3, 2026

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 329
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price target is $18.8, which is an increase of 290.04% from the latest price.

Price Target

$18.8

(290.04% upside)

Analyst Consensus: Strong Buy